Istesso

Executive Summary

Istesso is a UK-based biopharmaceutical company developing first-in-class oral regenerative medicines for chronic diseases via programmed disease resolution. Its platform focuses on mitochondrial Complex I modulators (MCMs), a novel class of small molecules designed to restore the body's natural repair mechanisms. Currently in Phase 2 clinical development, Istesso aims to shift the treatment paradigm from symptom management to tissue regeneration. The company's innovative approach targets a range of chronic conditions with high unmet need, leveraging its deep understanding of mitochondrial biology. With a strong scientific foundation and early clinical data suggesting disease-modifying potential, Istesso represents a compelling opportunity in the regenerative medicine space.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 topline data for lead MCM candidate in chronic inflammatory disease60% success
• Q2 2027Strategic partnership or licensing deal for MCM platform50% success
• Q3 2026Series B or C financing round to advance pipeline70% success